Method, assay, and kit for quantifying HIV protease inhibitors
AssigneeRoche Diagnostics Operations, Inc.
InventorsHerbert von der Eltz, Lili Arabshahi, Haijuan Li, Erasmus Huber
Life of this patent
Estimating the term…
Abstract
A method for quantifying an HIV protease inhibitor in a sample includes combining HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor. The HIV protease and the conjugate are capable of forming a detectable complex. The method also includes measuring the amount of the detectable complex, and relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.
Claims61
A method for quantifying an HIV protease inhibitor in a sample, comprising:
- combining an HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor, wherein the HIV protease and the conjugate form a detectable complex;
- measuring the amount of the detectable complex;
- and
- relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.
A method for quantifying an HIV protease inhibitor in a sample, comprising:
- combining an HIV protease, a conjugate comprising a carrier and at least two HIV protease inhibitor analogs linked to the carrier, and a sample suspected of containing an HIV protease inhibitor, wherein the HIV protease is immobilized on a surface of a microparticle, the HIV protease and the conjugate together undergo agglutination, and the sample is human serum or human plasma;
- measuring the agglutination;
- and
- relating the amount of agglutination to a concentration of the HIV protease inhibitor in the sample.
A method for quantifying an HIV protease inhibitor in a sample, comprising:
- combining a multivalent carrier comprising at least two HIV protease enzymes, a conjugate comprising a microparticle and an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor, wherein the HIV protease and the conjugate together undergo agglutination, and the sample is human serum or human plasma;
- measuring the agglutination;
- and
- relating the amount of agglutination to a concentration of the HIV protease inhibitor in the sample.
A method for quantifying an HIV protease inhibitor in a sample, comprising:
- combining an HIV protease, a conjugate comprising a label and an HIV protease inhibitor analog linked to the label, and a sample suspected of containing an HIV protease inhibitor, wherein the HIV protease and the conjugate together form a detectable complex, and the sample is human serum or human plasma;
- measuring the amount of the detectable complex by monitoring a change in fluorescence polarization;
- and
- relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.
A method for monitoring a concentration of an HIV protease inhibitor in an organism, comprising:
- administering a dose of an HIV protease inhibitor to the organism;
- obtaining a fluid sample from the organism;
- combining the sample with an HIV protease and a conjugate comprising an HIV protease inhibitor analog, wherein the HIV protease and the conjugate together form a detectable complex;
- measuring the amount of the detectable complex in the sample;
- and
- relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the organism.
A reagent for quantifying an HIV protease inhibitor in a sample, comprising:
- a particle comprising a surface;
- and
- HIV protease immobilized on the surface of the particle;
- wherein the HIV protease forms a detectable complex with a conjugate comprising an HIV protease inhibitor analog.
A kit for quantifying an HIV protease inhibitor in a sample, comprising:
- HIV protease;
- and
- a conjugate comprising an HIV protease inhibitor analog.
Dependencies are inferred from the claim text.